TR199900382T2 - Heterosiklik metaloproteaz inhibitörleri. - Google Patents

Heterosiklik metaloproteaz inhibitörleri.

Info

Publication number
TR199900382T2
TR199900382T2 TR1999/00382T TR9900382T TR199900382T2 TR 199900382 T2 TR199900382 T2 TR 199900382T2 TR 1999/00382 T TR1999/00382 T TR 1999/00382T TR 9900382 T TR9900382 T TR 9900382T TR 199900382 T2 TR199900382 T2 TR 199900382T2
Authority
TR
Turkey
Prior art keywords
compounds
metalloprotease inhibitors
pharmaceutical compositions
heterocyclic metalloprotease
inhibitors
Prior art date
Application number
TR1999/00382T
Other languages
English (en)
Inventor
Pikul Stanislaw
Lynn Mcdow-Dunham Kelly
De Biswanath
Olabisi Taiwo Yetunde
Gregory Almstead Neil
Sandler Bradley Rimma
George Natchus Michael
Lee Cupps Thomas
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Publication of TR199900382T2 publication Critical patent/TR199900382T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Bulus, istemlerde tarif edildigi haliyle (I) formülü bilesiklerini, ya da bu bilesiklerin bir optik izomeri, diastereomeri ya da enantiomeri, ya da farmasötik açidan kabul edilebilir bir tuzunu ya da biyo-hidrolize-edilebilir amidi, esteri ya da imidini temin etmektedir, bu maddeler metaloproteazlarin inhibitörleri olarak yararlidir. Ayni zamanda, metaloproteaz etkinligi ile vasiflanan hastaliklar, bozukluklar ve durumlarin, bu bilesikler ya da bu bilesikleri ihtiva eden farmasötik bilesim kullanilarak tedavi edilmesi için yöntemler ve farmasötik bilesimler de anlatilmistir.
TR1999/00382T 1996-08-28 1997-08-22 Heterosiklik metaloproteaz inhibitörleri. TR199900382T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2484696P 1996-08-28 1996-08-28

Publications (1)

Publication Number Publication Date
TR199900382T2 true TR199900382T2 (tr) 1999-05-21

Family

ID=21822698

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/00382T TR199900382T2 (tr) 1996-08-28 1997-08-22 Heterosiklik metaloproteaz inhibitörleri.

Country Status (25)

Country Link
US (2) US6121258A (tr)
EP (1) EP0923561B1 (tr)
JP (1) JP3347331B2 (tr)
KR (1) KR20000035920A (tr)
CN (1) CN1228772A (tr)
AR (1) AR009457A1 (tr)
AT (1) ATE226573T1 (tr)
AU (1) AU734834B2 (tr)
BR (1) BR9712085A (tr)
CA (1) CA2263917A1 (tr)
CO (1) CO4920240A1 (tr)
CZ (1) CZ62699A3 (tr)
DE (1) DE69716615T2 (tr)
DK (1) DK0923561T3 (tr)
HU (1) HUP0000210A3 (tr)
ID (1) ID18416A (tr)
IL (1) IL128664A (tr)
NO (1) NO314934B1 (tr)
NZ (1) NZ334254A (tr)
PE (1) PE2599A1 (tr)
PL (1) PL331795A1 (tr)
SK (1) SK25799A3 (tr)
TR (1) TR199900382T2 (tr)
WO (1) WO1998008823A1 (tr)
ZA (1) ZA977696B (tr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69716934T2 (de) * 1996-08-28 2003-07-31 The Procter & Gamble Company, Cincinnati 1,3-diheterozyklische metalloprotease inhibitoren
CA2298617A1 (en) 1997-07-31 1999-02-11 Yetunde Olabisi Taiwo Acyclic metalloprotease inhibitors
JP4750272B2 (ja) 1998-02-04 2011-08-17 ノバルティス アーゲー マトリックス分解メタロプロテイナーゼを阻害するスルホニルアミノ誘導体
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
US6846478B1 (en) 1998-02-27 2005-01-25 The Procter & Gamble Company Promoting whole body health
IL140040A0 (en) 1998-06-03 2002-02-10 Guilford Pharm Inc N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6509337B1 (en) * 1998-09-17 2003-01-21 Pfizer Inc. Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
CN1367678A (zh) * 1998-09-30 2002-09-04 宝洁公司 使用酮酰胺治疗脱发的方法
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
CN1329493A (zh) * 1998-12-02 2002-01-02 辉瑞产品公司 恢复p53家族蛋白质的构象稳定性的方法和组合物
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
AR022423A1 (es) * 1999-01-27 2002-09-04 American Cyanamid Co Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6358980B1 (en) 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6544984B1 (en) 1999-01-27 2003-04-08 American Cyanamid Company 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
MXPA01008857A (es) 1999-03-03 2002-07-02 Procter & Gamble Inhibidores de metaloproteasa dihetero sustituidos.
BR0008716A (pt) 1999-03-03 2002-09-24 Procter & Gamble Inibidores de metaloprotease contendo alquenil ou alquinil
CA2400862A1 (en) * 2000-02-21 2001-08-23 Noriko Mukai Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors
US8283135B2 (en) 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
MXPA03000043A (es) 2000-06-30 2003-10-15 Procter & Gamble Promocion de la salud en todo el cuerpo.
JP2005500270A (ja) * 2001-05-29 2005-01-06 ギルフォード ファーマシュウティカルズ インコーポレイテッド 手術の結果として発生した神経損傷を治療するための方法
BR0213736A (pt) 2001-11-01 2004-10-19 Wyeth Corp ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
CA2526222A1 (en) * 2003-05-16 2004-12-02 Arriva Pharmaceuticals, Inc. Treatment of respiratory disease associated with matrix metalloprotease inhibitors
WO2005065079A2 (en) * 2003-11-10 2005-07-21 Angiotech International Ag Medical implants and fibrosis-inducing agents
JP4777738B2 (ja) * 2004-10-14 2011-09-21 株式会社 資生堂 Ａｄａｍ活性阻害物質によるしわの防止または改善
JP2007119444A (ja) * 2005-09-29 2007-05-17 Shiseido Co Ltd Ａｄａｍ阻害剤によるしわの防止または改善

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601368D0 (en) * 1986-01-21 1986-02-26 Ici America Inc Hydroxamic acids
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8919251D0 (en) * 1989-08-24 1989-10-04 British Bio Technology Compounds
DE4011172A1 (de) * 1990-04-06 1991-10-10 Degussa Verbindungen zur bekaempfung von pflanzenkrankheiten
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
GB9107368D0 (en) * 1991-04-08 1991-05-22 Smithkline Beecham Plc Novel compounds
IL98681A (en) * 1991-06-30 1997-06-10 Yeda Rehovot And Dev Company L Pharmaceutical compositions comprising hydroxamate derivatives for iron removal from mammalian cells and from pathogenic organisms and some novel hydroxamate derivatives
DE4127842A1 (de) * 1991-08-22 1993-02-25 Rhone Poulenc Rorer Gmbh 5-((omega)-arylalky)-2-thienyl alkansaeuren, ihre salze und/oder ihre derivate
JPH05125029A (ja) * 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
AU3899193A (en) * 1992-04-07 1993-11-08 British Bio-Technology Limited Hydroxamic acid based collagenase and cytokine inhibitors
AU4267293A (en) * 1992-05-01 1993-11-29 British Biotech Pharmaceuticals Limited Use of MMP inhibitors
AU666727B2 (en) * 1992-06-25 1996-02-22 F. Hoffmann-La Roche Ag Hydroxamic acid derivatives
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9411598D0 (en) * 1994-06-09 1994-08-03 Hoffmann La Roche Hydroxamic acid derivatives
CA2193691A1 (en) * 1994-06-22 1995-12-28 Andrew Miller Metalloproteinase inhibitors
ES2153031T4 (es) * 1995-04-20 2001-05-16 Pfizer Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
US6207672B1 (en) * 1995-11-13 2001-03-27 Aventis Pharma Deutschland Gmbh Cyclic and heterocyclic N-substituted α-iminohydroxamic and carboxyclic acids
ES2233275T3 (es) * 1995-12-08 2005-06-16 Agouron Pharmaceuticals, Inc. Intermediarios que sirven para la preparacion de inhibidores de metaloproteinasas.
ATE225343T1 (de) * 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren

Also Published As

Publication number Publication date
JP3347331B2 (ja) 2002-11-20
PE2599A1 (es) 1999-03-03
SK25799A3 (en) 1999-12-10
WO1998008823A1 (en) 1998-03-05
AR009457A1 (es) 2000-04-26
HUP0000210A2 (hu) 2001-04-28
CZ62699A3 (cs) 1999-07-14
DE69716615T2 (de) 2003-06-18
ID18416A (id) 1998-04-09
US6121258A (en) 2000-09-19
PL331795A1 (en) 1999-08-02
AU4153097A (en) 1998-03-19
EP0923561B1 (en) 2002-10-23
US6399598B1 (en) 2002-06-04
CA2263917A1 (en) 1998-03-05
NZ334254A (en) 2000-11-24
NO990759L (no) 1999-04-27
NO314934B1 (no) 2003-06-16
BR9712085A (pt) 2000-10-24
ZA977696B (en) 1998-02-23
KR20000035920A (ko) 2000-06-26
IL128664A0 (en) 2000-01-31
CN1228772A (zh) 1999-09-15
AU734834B2 (en) 2001-06-21
DK0923561T3 (da) 2003-02-24
HUP0000210A3 (en) 2001-07-30
NO990759D0 (no) 1999-02-18
DE69716615D1 (de) 2002-11-28
IL128664A (en) 2003-07-06
ATE226573T1 (de) 2002-11-15
JP2000516953A (ja) 2000-12-19
CO4920240A1 (es) 2000-05-29
EP0923561A1 (en) 1999-06-23

Similar Documents

Publication Publication Date Title
TR199900400T2 (tr) Heterosiklik metaloproteaz inhibitörleri.
TR199900382T2 (tr) Heterosiklik metaloproteaz inhibitörleri.
TR199900383T2 (tr) 1,3-Diheterosiklik metaloproteaz inhibitörleri.
TR199900429T2 (tr) Spirosiklik metaloproteaz inhibitörleri.
TR199900399T2 (tr) Matris metaloproteaz inhibitörleri olarak fosfinik asit amidleri.
WO1999006340A3 (en) Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
TR199900401T2 (tr) Bidentat metaloproteaz inhibitörleri.
EA200100588A1 (ru) Пиперидины как модуляторы ccr5
BG104780A (en) Inhibitors of phospholipase enzymes
EA200100992A1 (ru) Ингибиторы фермента impdh
NO20005237D0 (no) Heterocyklisk substituerte amider anvendt som calpain- inhibitorer
EA200100972A1 (ru) Новые соединения и композиции как ингибиторы протеаз
PT927161E (pt) Aminas ciclicas substituidas inibidoras de metaloproteases
EA200501658A2 (ru) Производные азаспироалканов в качестве ингибиторов металлопротеаз
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
TR200002971T2 (tr) İkameli pirolidin hidroksamat metaloproteaz inhibitörleri
TR200102524T2 (tr) Dihetero sübstitüe edilmiş metaloproteaz inhibitörleri.
RU94036448A (ru) Производные галантамина и фармацевтическая композиция
EA200100774A1 (ru) Гетероциклические производные с функциональными группами (варианты), фармацевтическая композиция и комбинация, способ модулирования активности рецептора хемокина (варианты), способ профилактики инфицирования вич и лечения инфекции вич, замедления проявления спид и лечения спид, способ лечения воспалительных процессов
KR20000005379A (en) Isatin derivatives as acetylcholinesterase inhibitors and analgesics
EE200200591A (et) Püridiin-1-oksiidderivaat ja meetod selle muutmiseks farmatseutiliselt efektiivseteks ühenditeks
BR0109328A (pt) Inibidores de metaloprotease n-substituìdos, contendo cadeia lateral heterocìclica
PT1109560E (pt) Compostos uteis como inidores de aicarft
TR200200977T2 (tr) Beta konumunda iki kere sübstitüe edilmiş metaloproteaz engelleyiciler
RU95106652A (ru) Оптически активные производные карбоксамида, аналгезирующее средство